- Table of Contents
We validate the specificity of these antibodies to Septin-9 by testing them on tissues known to express SEPTIN9 positively and negatively. Browse below to find the SEPTIN9 antibody that suites your experiment. We have 4 of these antibodies and many publications and validation images.
If you cannot find antibodies that fit your needs, contact us for making custom antibodies. We have a full suite of custom antibody services covering from research to diagnostic and therapeutic applications.
Facts about Septin-9.
May play a role in the internalization of two intracellular microbial pathogens, Listeria monocytogenes and Shigella flexneri. .
|TRAFAC class TrmE-Era-EngA-EngB-Septin-like GTPase superfamily|
|Sequence:||17; NC_000017.11 (77281499..77500596)|
Widely expressed. Isoforms are differentially expressed in testes, kidney, liver heart, spleen, brain, peripheral blood leukocytes, skeletal muscle and kidney. Specific isoforms appear to demonstrate tissue specificity. Isoform 5 is the most highly expressed in fetal tissue. Isoform 1 is detected in all tissues except the brain and thymus, while isoform 2, isoform 3, and isoform 4 are detected at low levels in approximately half of the fetal tissues.
Cytoplasm, cytoskeleton. In an epithelial cell line, concentrates at cell-cell contact areas. After TGF-beta1 treatment and induction of epithelial to mesenchymal transition, colocalizes partly with actin stress fibers. During bacterial infection, displays a collar shape structure next to actin at the pole of invading bacteria.
You might be curious to know more about the SEPT9 indicator, which is an upstream negative effector of RhoA. This marker is a promising candidate for early diagnosis, targeted therapy, recurrence monitoring, and prognosis. It can also be detected by PCR or plasma specimens. Listed below are some of its best uses.
Boster Bio founder Steven Boster has been long interested in the potential of Boster Bio's mSEPT9 technology to detect antigens within cells. He developed his first product in 1993 and has since developed hundreds of primary antibodies for IHC. Boster Bio became China's largest anti-globalization company in the late 1990s. The company has also developed a proprietary ELISA platform called PicoKine that utilizes trade secrets and delivers high-sensitivity ELISA kits.
Researchers can detect the presence and type of cancer-related or inflammatory cells by using the Boster bio SEPTIN9 anti CD274 antibody. The antibody reacts on B cells with the protein CD274, and this is what the antibody does. It also contains the antibodies required to perform immunofluorescence studies. Boster Bio's SEPTIN9 anti CD274 antibodies are available as a kit for 96 testing with a sensitivity of 12 parts per million.
Foundation One Liquid CDx tests for genetic mutations in 324 genes. It also detects two genomic signatures in any solid tumour. The results help identify patients who may benefit from targeted therapy. American Society of Clinical Oncology created guidelines for clinical practice regarding biomarkers used to detect cancer. These tests may be used in a variety o clinical settings such as early detection, diagnosis and monitoring for recurrence.
Recent advancements in high-throughput profiling technologies have led to the development of biomarkers to supplement clinical examinations. Although only a few biomarkers have high sensitivity and specificity, these blood tests are increasingly useful in cancer screening and diagnosis. Tissue biopsies, though important for early detection of lung cancer, are not invasive and don't capture heterogeneity.
Both radiologic and operative techniques can be both cost-effective and affordable. They allow doctors and nurses to monitor and measure patients' responses to treatments in a more precise manner. This means patients can be treated earlier than waiting for a diagnosis. Depending on the type of cancer and treatment chosen, the wait can be up to two to four years or 62 weeks.
The patient's tumor marker levels rise during cancer treatment. These markers, also known as tumor cells, may help track the treatment's progress. Blood tests cannot detect a recurrence in women who have not been diagnosed with cancer. A physician who has a detailed understanding of the patient's medical history is better equipped than others to provide personalized information about the chances of a recurrence. They can alert patients to the possibility of a recurrence, and offer ways to reduce the risk.
The SEPT9 test was developed based on the deVos PCR detection protocol, which was used in the PRESEPT screening study. The new method used a robust duplex reaction that detected both SEPT9 (and ACTB) using different fluorescent tags. The two methods share the same reagents and are completed in about 24 hours. Each takes approximately four hours of hands on time.
In one study SEPT9methylation was tested on 98 healthy controls. All subjects had no history of colon cancer and were therefore able to be tested without further testing. The study showed that the Boster Bio SEPTTIN9 marker is detected in plasma specimens of patients with and without CRC. The assay was highly sensitive and specific, with the sensitivity of 88%.
A study using SEPT9 assays identified 45 types of CRCs. This includes all staged cancers. The overall sensitivity was 90% and more than half the samples were from the early stages of the disease. Nearly half of the subjects tested had advanced stage disease. This indicates that the marker is not specific for early-stage CRCs. SEPT9 detection in plasma specimens has been shown to have low sensitivity, so it may not be the best screening method.
Multiplex panels based ctDNA show greater specificity and sensitivity than PCR. Multiplex panels based on ctDNA actually have the highest sensitivity as well as specificity of all molecular testing. Patients can get treatment faster if they have undetectable mutant SEPTIN9-cfDNA in plasma samples. And because the markers are nonoverlapping, this can be a useful diagnostic tool for cancer patients.
Boster Bio SEPTIN9 markers are a new DNA microarray assay that can detect this human gene. The test involves amplifying DNA using bisulfite -converted DNA from tissue or plasma samples. The PCR product contains a 146 basepair-long segment of the LINE-1 RNA sequence. The PCR kits can be used in conjunction with a CFX96 PCR system and a thermocycling or temperature program.
ELISA is a method that uses a plate to detect peptides, proteins and antibodies. Specific antibodies must bind to the target antibody and be conjugated. To determine the enzyme's activity, the substrate is incubated. The key element of the detection strategy's success is the high specificity and interaction between the antibody and the antigen. Boster Bio Picokine ELISA kits are renowned for their sensitivity and are used by scientists around the world.
Boster bio sells antibodies to the SPTIN9 protein. They are available in monoclonal or polyclonal forms, and can react with many animal samples. Boster Bio uses mouse and rabbit as models for testing. RBFOX3 regulates alternative splicing pre-mRNA. This antibody detects it in neuronal tissue. This assay is useful for research projects and multiple uses.
Optimized plate-coating conditions are required for ELISA. The assay microplate needs to have a protein binding capacity of 400 ng/cm2; the CV (coefficient variation) must be less that 1%. The signal intensity depends on the type of signal. Colorimetric signals are detected using transparent flat-bottom plates of polystyrene; fluorescent signals are detected using opaque plates that are either black or white.
Boster Bio sells the anti-CD274 antibody. It reacts with both human and mouse PDL1 proteins. This antibody is excellent for immunofluorescence research and is a good choice to study animal tissues. It can be purchased from many online retailers. It has a sensitivity level of 12 ppg/ml. It is useful for determining the proportion of B-cells involved in an inflammatory response.